Archived explainer. For the current picture see today's NVAX page.
NOVAVAX INC (NVAX) is up +20.08% in the latest session. Our newswire has captured 4 stories on NVAX across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 61/100).
NVAX stock surged 20.08% to $12.56 in a single session, driven by a mix of speculative retail trading and industry-specific developments. The rise came despite a lack of confirmed news or government action. Retail traders have been active on platforms like Stocktwits, linking the stock’s move to unconfirmed reports about potential contract awards and a rumored favorable safety profile for Novavax’s Matrix-M technology. Meanwhile, a separate late-stage success by a rival vaccine developer, Vaxcyte, added momentum to the broader vaccine sector.
The stock’s sharp rise followed a combination of speculative activity and news from related vaccine companies. Vaxcyte announced that its experimental pneumonia vaccine met key goals in a late-stage trial, contributing to a broader sector rally. At the same time, retail traders on social media platforms were circulating unconfirmed reports that Novavax’s Matrix-M adjuvant showed a favorable safety profile with mostly mild side effects. These reports, though not backed by official data, spurred renewed interest in the stock. Additionally, Sanofi’s decision to carry the Nuvaxovid vaccine into the fall season was cited as a contributing factor, with Novavax as the licensor.
Over the last 8 sessions, NVAX has risen 18.5% from $10.60 to $12.56, reaching a new 52-week high on October 5. The stock has seen unusual options activity, with 14 notable prints and a call premium of $5.9 million versus $171,000 in put premium. The largest single print was valued at $1.5 million. The stock’s fundamentals remain weak, with a market cap of $1.7 billion and a trailing 12-month revenue decline of 61.6%. Despite the recent rally, the stock is still unprofitable with an EPS TTM of -1.52 and a net margin of -59.9%.
With no earnings date scheduled in the near term, investors should monitor coverage breadth and options flow for signs of continued retail-driven momentum.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
No plague case has been confirmed, and no government orders have been announced, but outbreak-linked stocks jumped anyway.
Vaxcyte said earlier on Monday that its experimental pneumonia vaccine, VAX-31, met the main goals of a late-stage study in adults 50 and older.
Sanofi is carrying the Nuvaxovid COVID-19 shot into the fall vaccination season, and buyers are rewarding shares of licensor Novavax (NASDAQ:NVAX) far more heavily than the rest of biotech. Novavax stock has rose 17% during afternoon trading, reaching $12.28, a move that stands well apart from its closest vaccine rivals and the broader sector. Checking […]
Why is Novavax stock surging today?
More on NVAX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier NVAX move explainers: 2026-10-06 · 2026-10-05 · 2026-09-10 · 2026-09-02 · 2026-09-01 · 2026-08-28